Cargando…
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
Since its first approval in 2006, 1 year of adjuvant trastuzumab has been the standard of care for early-stage HER2-positive breast cancer. Nevertheless, the optimal duration of adjuvant trastuzumab was uncertain, and the standard 12-month duration has been questioned by a number of different trials...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908056/ https://www.ncbi.nlm.nih.gov/pubmed/35272131 http://dx.doi.org/10.1016/j.esmoop.2022.100428 |